Changeflow GovPing Pharma & Drug Safety Crystalline Solid Forms of BET Inhibitor for Ca...
Routine Notice Added Draft

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

What changed

The USPTO published a patent application covering crystalline solid forms of BET (Bromodomain and Extra-Terminal) protein inhibitors including BRD2, BRD3, BRD4, and BRD-t. The application (US20260092065A1, filed as 19337664) discloses novel solid forms of the inhibitor compound, methods of preparing these forms, and intermediates in their preparation. The compounds are directed toward treating diseases including cancer.

This is a provisional patent filing with no immediate compliance requirements or deadlines. Pharmaceutical companies and researchers developing BET inhibitors for oncology indications may want to review the application to assess freedom-to-operate considerations or potential licensing opportunities. No regulatory submissions or actions are required at this stage.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CRYSTALLINE SOLID FORMS OF A BET INHIBITOR

Application US20260092065A1 Kind: A1 Apr 02, 2026

Inventors

Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li

Abstract

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

CPC Classifications

C07D 471/04 A01M 31/06 C07D 471/02 C07F 5/025 C07B 2200/13

Filing Date

2025-09-23

Application No.

19337664

View original document →

Named provisions

Crystalline Solid Forms BET Protein Inhibition Cancer Treatment Methods

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
September 23rd, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092065A1 / 19337664

Who this affects

Applies to
Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical Research Drug Development Cancer Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.